1. Home
  2. ZD vs BEAM Comparison

ZD vs BEAM Comparison

Compare ZD & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZD
  • BEAM
  • Stock Information
  • Founded
  • ZD 1995
  • BEAM 2017
  • Country
  • ZD United States
  • BEAM United States
  • Employees
  • ZD N/A
  • BEAM N/A
  • Industry
  • ZD Advertising
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ZD Consumer Discretionary
  • BEAM Health Care
  • Exchange
  • ZD Nasdaq
  • BEAM Nasdaq
  • Market Cap
  • ZD N/A
  • BEAM 1.9B
  • IPO Year
  • ZD 1999
  • BEAM 2020
  • Fundamental
  • Price
  • ZD $54.99
  • BEAM $24.45
  • Analyst Decision
  • ZD Buy
  • BEAM Buy
  • Analyst Count
  • ZD 8
  • BEAM 10
  • Target Price
  • ZD $70.50
  • BEAM $47.67
  • AVG Volume (30 Days)
  • ZD 490.7K
  • BEAM 1.1M
  • Earning Date
  • ZD 02-19-2025
  • BEAM 02-25-2025
  • Dividend Yield
  • ZD N/A
  • BEAM N/A
  • EPS Growth
  • ZD 41.38
  • BEAM N/A
  • EPS
  • ZD 1.38
  • BEAM N/A
  • Revenue
  • ZD $1,378,750,000.00
  • BEAM $349,643,000.00
  • Revenue This Year
  • ZD $6.74
  • BEAM N/A
  • Revenue Next Year
  • ZD $5.56
  • BEAM $10.82
  • P/E Ratio
  • ZD $39.49
  • BEAM N/A
  • Revenue Growth
  • ZD 0.58
  • BEAM 328.73
  • 52 Week Low
  • ZD $37.76
  • BEAM $20.84
  • 52 Week High
  • ZD $70.90
  • BEAM $49.50
  • Technical
  • Relative Strength Index (RSI)
  • ZD 47.02
  • BEAM 41.52
  • Support Level
  • ZD $53.62
  • BEAM $24.96
  • Resistance Level
  • ZD $56.97
  • BEAM $29.52
  • Average True Range (ATR)
  • ZD 1.82
  • BEAM 1.64
  • MACD
  • ZD -0.51
  • BEAM -0.50
  • Stochastic Oscillator
  • ZD 29.79
  • BEAM 11.02

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

Share on Social Networks: